We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. Hermiston has over 20 years of R&D experience in the life science industry, having held senior positions at Bayer Healthcare, Berlex Biosciences and Onyx Pharmaceuticals. In these roles he has been responsible for assembling and managing teams of scientists and research associates, most recently as the head of Bayer HealthCare’s R&D site located in Mission Bay in San Francisco. While at Bayer Dr. Hermiston co-chaired the Early Research portfolio in Hematology and the Early Research portfolio in Immuno-Oncology and Antibody Drug Conjugates. While at Onyx, he was responsible for the oncolytic virus research program and at Berlex invented the oncolytic virus, Enadenotucirev, that is currently in Phase II clinical trials in partnership with BMS. Dr. Hermiston recently completed the acquisition of the novel PS targeting technology from Bayer and formed GLAdiator Biosciences to pursue its applications in oncology.
This speaker's sessions: